VivoSeq
Infectious Disease

Infective Endocarditis

22

Pipeline Programs↗

5

Active Trials↗

11

Companies Involved↗

Infective Endocarditis is an emerging landscape with 22 programs across 11 companies. The most active players are AbbVie, Adaptive Phage Therapeutics, Inc., Merck & Co.. 16 therapies are approved with 1 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

11/100

Mech. Concentration

33/100

Completion Rate

56/100

Attrition Rate

22/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

AbbVie logo

AbbVie

1 program

Phase 2A

Adaptive Phage Therapeutics, Inc.

1 program

Phase 3Merck & Co. logo

Merck & Co.

2 programs

ApprovedBayer logo

Bayer

2 programs

ApprovedH

Hikma Pharmaceuticals LLC

1 program

ApprovedSanofi logo

Sanofi

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

18

clinical trials

Completed5 · 28%
Recruiting4 · 22%
Terminated4 · 22%
Unknown status4 · 22%
Not yet recruiting1 · 6%

Clinical Trials

Trial Activity

18 trials

Ampicillin and Ceftriaxone for the Treatment of Enterococcus Faecalis Infective Endocarditis.
Recruiting·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 4·NCT06423898·284 enrolled
Contribution of PET/CT With Gallium 68 Citrate (68Ga-PET/CT) for the Diagnosis of Prosthetic Valve Infective Endocarditis
Recruiting·UUniversity Hospital, Bordeaux·Phase 2·NCT05446376·40 enrolled
Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis
Recruiting·—·Phase 3·NCT06870409·30 enrolled
Development and Validation of An Algorithm of Etiological Diagnosis of Infective Endocarditis in Adults: An Open-Label Multicenter Randomized Clinical Trial
Recruiting·II.M. Sechenov First Moscow State Medical University·Preclinical·NCT07682389·128 enrolled
From Commensalism to Pathogenicity: Exploring the Pathophysiology of Bacteremia to Better Understand Enterococcus Faecalis Infective Endocarditis
Not yet recruiting·UUniversity Hospital, Clermont-Ferrand·N/A·NCT07313865·90 enrolled
Early Feasibility Study of Somatostatin Receptors PET Imaging for the Diagnosis of Infective Endocarditis
Completed·—·Phase 2·NCT05183555·14 enrolled
Fosfomycin Plus Imipenem for Treatment of Infective Endocarditis
Completed·—·Phase 4·NCT00871104·50 enrolled
Daptomycin in the Treatment of Subjects With Infective Endocarditis or Bacteremia Due to S. Aureus
Completed·Merck & Co. logoMerck & Co.·Phase 3·NCT00093067
Evaluation of an Antibiotic Regimen Pharmacokinetic Applicable to Enterococcus Faecalis Infective Endocarditis
Completed·FFundación Pública Andaluza para la gestión de la Investigación en Sevilla·Phase 2·NCT03681431·12 enrolled
The Effect of Sodium Bicarbonate on Postoperative Renal Function in Infective Endocarditis Patients Undergoing Open Heart Surgery
Completed·YYonsei University·Phase 4·NCT01920126·70 enrolled
Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis
Terminated·—·Phase 4·NCT04222257·20 enrolled
Phase 4 Efficacy and Safety Study of Cubicin® With and Without Combination Therapy in S. Aureus Infective Endocarditis (SAIE)
Terminated·Merck & Co. logoMerck & Co.·Phase 4·NCT00638157·24 enrolled
Assessment of Radiolabeled rhAnnexin V-128 in Infective Endocarditis
Terminated·IInstitut National de la Santé Et de la Recherche Médicale, France·Phase 1/2·NCT02459613·11 enrolled
Efficacy and Safety of Dalbavancin Compared to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated Bacteremia or Infective Endocarditis
Terminated·AbbVie logoAbbVie·Phase 2·NCT03148756·2 enrolled
Prosthetic Valve Sweing Ring Injection by Antiboitics Can Affect the Rate of Postoperative Infective Endocarditis?
Unknown status·—·N/A·NCT05455788·300 enrolled
Page 1 of 2

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)